Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in Hyperinflated COPD Patients
NCT02451540Phase 2Terminated
- Sponsor
- FLUIDDA
- Start
- Sep 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast Arm with Placebo Arm (2 arms). Primary endpoints: Changes in Airway volume at 3 months, Changes in Airway resistance at 3 months and 7 more. Started Sep 2015; status: terminated.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02451540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451540.